# Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

> **NCT04409288** · PHASE3 · TERMINATED · sponsor: **Chinese University of Hong Kong** · enrollment: 74 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04409288
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-20
- **Primary completion:** 2023-10-16
- **Final completion:** 2023-10-16
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** Endpoint reached
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04409288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04409288, "Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04409288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*